Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737722 · ClinicalTrials.gov registry record · Phase 1
Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
A Phase 1 study of Diabetic Foot Infections, sponsored by Lakewood-Amedex.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 3
- Study locations
NCT02737722 is a Phase 1 study of Diabetic Foot Infections that has completed, run by Lakewood-Amedex. The registered enrollment target is 31 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02737722, a Phase 1 study of Diabetic Foot Infections, has completed, sponsored by Lakewood-Amedex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS score of 0 to 3 and DFI wound score of 1 to 3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bisphosphocin Nu-3
Study Locations (3)
California
- Center for Clinical Research, Inc. - San Francisco
Florida
- Journey Research, Inc. - Oldsmar
Tennessee
- Clinical Research Solutions - Franklin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02737722
The ClinicalTrials.gov registry entry for NCT02737722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakewood-Amedex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Foot Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02737722 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02737722 about?
NCT02737722 is a clinical study titled "Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus". Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS score of 0 to 3 and DFI wound score of 1 to 3.
What is the current status of trial NCT02737722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2016-04. Estimated completion is 2018-02.
What conditions does trial NCT02737722 study?
This clinical trial studies the following conditions: Diabetic Foot Infections.
What interventions are being tested in trial NCT02737722?
The interventions under investigation include: Placebo (DRUG), Bisphosphocin Nu-3 (DRUG).
Who is sponsoring clinical trial NCT02737722?
This trial is sponsored by Lakewood-Amedex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02737722 being conducted?
This trial has 3 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.